Bone scan vs. PET/CT in the assessment of skeletal metastatic disease progression.

This article discusses the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and bone scans in the detection of suspected skeletal metastatic disease and in assessment of treatment response on a 68-year-old woman with known skeletal metastatic disease. The clinical history of the patient is described, as well as the results of the physical and laboratory examinations performed on the patient.